RxDoctor Payments Data

Angela Genovese, APRN

Family · Norman, OKNPI 1891182333

Payments from drug & device makers

$1,648in general payments, 2019–2025

Across 56 payments — averaging $29.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Corcept Therapeutics$513
  • AstraZeneca$237
  • Ascensia Diabetes Care US Inc.$204
  • Mannkind Corporation$178
  • Lilly USA, LLC$166
  • Xeris Pharmaceuticals, Inc.$85
  • plus $266 from 9 others

What the payments were for

  • Food & beverage$1,648100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,648 in reported general payments places this provider in the 75th percentile of 2,026 family providers in Oklahoma.

See all family providers in Oklahoma

Medicare billing

Part B allowed, 2024
$20,496
Medicare patients
38
Services billed
121

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide35$43,182
JardianceEmpagliflozin20$36,063
TrulicityDulaglutide15$14,583
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$9,914
Synjardy XrEmpagliflozin/Metformin Hcl13$7,471
Lacosamide11$939
Omeprazole26$703
Metformin Hcl ErMetformin Hcl30$688
Pioglitazone Hcl12$481
Gabapentin30$425
Albuterol Sulfate HfaAlbuterol Sulfate16$361
Metformin Hcl14$227
Duloxetine Hcl21$200
Primidone12$192
Losartan Potassium18$190

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$31$43,18235 claims
Lilly USA, LLCTrulicity$166$14,58315 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,026 family providers in Oklahoma.

Other family in Norman

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →